Recent Quotes (30 days)

You have no recent quotes
chg | %

Neurokine Pharmaceuticals Inc  

(Public, OTCMKTS:NEUKF)   Watch this stock  
Find more results for OTC:NEUKF
0.0068
0.0000 (0.00%)
Delayed:   3:35PM EDT
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range     -
52 week 0.00 - 0.04
Open     -
Vol / Avg. 0.00/5,202.00
Mkt cap 787,220.00
P/E     -
Div/yield     -
EPS -0.01
Shares 115.77M
Beta -1.96
Inst. own     -

Key stats and ratios

Q3 (Jul '14) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -1602.64% -
Return on average equity - -
CDP Score - -

Address

c/o Macdonald Tuskey 4th Floor, 570 Granville Street
VANCOUVER, BC V6C 3P1
Canada
+1-604-2210595 (Phone)
+1-604-2250588 (Fax)

Website links

Description

Neurokine Pharmaceuticals Inc. is a development-stage biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutic pharmaceutical products. Its research and development activities are focused on assessing known drugs and compounds, developing hypotheses concerning their usage for new indications (diseases), and conducting experimentation and clinical research to test those hypotheses. As of March 12, 2012, the Company had identified three anti-inflammatory products, which included NK001, NK002 and NK-003. NK-001 is an application of the generic drug Etanercept for treating neurocognitive impairment in Coronary Artery Bypass Graft (CABG) surgery patients. NK-002 is a development-stage drug for the treatment of Alzheimer´┐Żs disease.